Alison Stopeck

17.8k citations

159 papers · 12.7k indexed · 7 hit papers · h-index 43

Impact in

Oncology top 0.1%
- Cancer Cells and Metastasis
- Bone health and treatments
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
Cancer Research top 0.2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 102
- Bone health and treatments 42
- Cancer Treatment and Pharmacology 25
- Cancer Diagnosis and Treatment 17
- HER2/EGFR in Cancer Research 15
Radiology, Nuclear Medicine and Imaging 43
- Radiopharmaceutical Chemistry and Applications 23

Co-authors: Daniel F. Hayes Michael Craig Miller G. Thomas Budd Jeri Matera Leon W.M.M. Terstappen Gerald V. Doyle Massimo Cristofanilli W. Jeffrey Allard
Journals: Journal of Clinical Oncology (28 papers)Cancer Research (15 papers)Clinical Cancer Research (8 papers)European Journal of Cancer (6 papers)Blood (5 papers)
Partner nations: United States Canada France

In The Last Decade

Alison Stopeck

157 papers receiving 12.4k citations

Hit Papers

7 papers align trajectories log scale

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years 2016 · 411 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 New England Journal of Medicine
2012 European Journal of Cancer
2011 Annals of Oncology
2010 Journal of Clinical Oncology
2006 Clinical Cancer Research
2005 Journal of Clinical Oncology
2004 New England Journal of Medicine

Peers

Countries citing papers authored by Alison Stopeck

Since Specialization

Citations

This map shows the geographic impact of Alison Stopeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Stopeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Stopeck more than expected).

Fields of papers citing papers by Alison Stopeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Stopeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Stopeck. The network helps show where Alison Stopeck may publish in the future.

Co-authors

The 25 scholars most cited alongside Alison Stopeck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alison Stopeck Line = papers co-authored together Alison Stopeck links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer Clinical Cancer Research ·Elena Shagisultanova, William J. Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck, Hannah Parris, Dexiang Gao, Tessa McSpadden, José Mayordomo, Jennifer R. Diamond, Peter Kabos, Virginia F. Borges	2023	8
2	Utility of Stereotactic Body Radiation Therapy in Establishing Local Control for Patients With Invasive Breast Cancer Not Undergoing Definitive Surgery International Journal of Radiation OncologyBiologyPhysics ·Ewa Zabrocka, S.A. Polce, John Roberson, Jieying Wu, Jules Cohen, Lea Baer, Alison Stopeck, Samuel Ryu, A. Stessin	2023	4
3	Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer Breast Cancer Research and Treatment ·Jessica A. Martinez, Betsy C. Wertheim, Denise J. Roe, Pavani Chalasani, Jules Cohen, Lea Baer, H.‐H. Sherry Chow, Alison Stopeck, Patricia A. Thompson	2022	6
4	Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach Journal of bone oncology ·Dionna Jacobson, Benoît Cadieux, Celestia S. Higano, David H. Henry, Basia A. Bachmann, Marko Rehn, Alison Stopeck, Hossam Saad	2022	16
5	Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval Journal of bone oncology ·Benoît Cadieux, Robert E. Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck	2022	41
6	Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors Clinical Cancer Research ·Patricia A. Thompson, Chuan Huang, Jie Yang, Betsy C. Wertheim, Denise J. Roe, Xiaoyue Zhang, Jie Ding, Pavani Chalasani, Christina Preece, Jessica A. Martinez, H.‐H. Sherry Chow, Alison Stopeck	2021	17
7	Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer Clinical Breast Cancer ·Peter A. Kaufman, Hans Wildiers, Gilles Freyer, Margaret Kemeny, Anthony Gonçalvès, Guy Jérusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanayakkara, Benjamin Wu, Cheryl A. Pickett	2018	6
8	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents Clinical Cancer Research ·Allan Lipton, Matthew Smith, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Neal D. Shore, Fred Saad, Andrew Spencer, Li Zhu, Douglas Warner	2016	32
9	Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol BMC Cancer ·Jessica A. Martinez, Pavani Chalasani, Cynthia A. Thomson, Denise J. Roe, María I. Altbach, Jean‐Philippe Galons, Alison Stopeck, Patricia A. Thompson, Diana Evelyn Villa-Guillen, H.‐H. Sherry Chow	2016	30
10	A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer Open Repository and Bibliography (University of Liège) ·Peter A. Kaufman, Gilles Freyer, Margaret Kemeny, Anthony Gonçalvès, Guy Jérusalem, Alison Stopeck, N. Vrindavanam, Florence Dalenc, Nadeeshani Nanayakkara, Benjamin Wu, Cheryl A. Pickett, Hans Wildiers	2015	1
11	Impact of denosumab on bone mass in cancer patients Clinical Pharmacology Advances and Applications ·Alison Stopeck, Ursa Brown-Glaberman	2013	8
12	Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors Biologics ·Alison Stopeck, Ursa Brown-Glaberman	2012	29
13	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Clinical Cancer Research ·Shanu Modi, Alison Stopeck, Hannah Linden, David B. Solit, Sarat Chandarlapaty, Neal Rosen, Gabriella D’Andrea, Maura N. Dickler, Mary Ellen Moynahan, Steven Sugarman, Weining Ma, Sujata Patil, Larry Norton, Alison L. Hannah, Clifford A. Hudis	2011	328
14	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun Hit paper breakdown →	2010	1102
15	Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia Haemophilia ·Gregory J. Gerstner, Mary Lou Damiano, Abdel Rahman El Tom, Christina Worman, Wendy Schultz, Michael Recht, Alison Stopeck	2009	105
16	Diagnosing and Treating Breast Cancer in Elderly Women: A Call for Improved Understanding Journal of the American Geriatrics Society ·Leona Downey, Robert B. Livingston, Alison Stopeck	2007	18
17	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer New England Journal of Medicine ·Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis, Alison Stopeck, Jeri Matera, Michael Craig Miller, James M. Reuben, Gerald V. Doyle, W. Jeffrey Allard, Leon W.M.M. Terstappen, Daniel F. Hayes Hit paper breakdown →	2004	3546
18	Radial fast spin‐echo method for T2‐weighted imaging and T2 mapping of the liver Journal of Magnetic Resonance Imaging ·María I. Altbach, Eric K. Outwater, Theodore P. Trouard, Elizabeth A. Krupinski, Rebecca J. Theilmann, Alison Stopeck, Mitsuko Kono, Arthur F. Gmitro	2002	58
19	Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells Cancer Gene Therapy ·Paul Clark, Alison Stopeck, Jacqueline L. Brailey, Qing Wang, James G. McArthur, Mitch H Finer, Evan M. Hersh	1999	29
20	Interferon γ (IFNγ) gene transfer of an EMT6 tumor that is poorly responsive to IFNγ stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC Cancer Immunology Immunotherapy ·Monica C. Panelli, E. Wang, Shanxiang Shen, Samuel F. Schluter, Ralph M. Bernstein, Evan M. Hersh, Alison Stopeck, R Gangavalli, Jack R. Barber, Douglas J. Jolly, E T Akporiaye	1996	22

About Alison Stopeck

Alison Stopeck is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research, Pulmonary and Respiratory Medicine and Orthopedics and Sports Medicine, having authored 159 papers that have together received 12.7k indexed citations. Recurring topics across this work include Bone health and treatments (42 papers), Cancer Treatment and Pharmacology (25 papers), Radiopharmaceutical Chemistry and Applications (23 papers), Cancer Diagnosis and Treatment (17 papers), Advanced Breast Cancer Therapies (16 papers), HER2/EGFR in Cancer Research (15 papers), Breast Cancer Treatment Studies (12 papers) and Management of metastatic bone disease (11 papers). The work is most often cited by research in Oncology (8.6k citations), Cancer Research (3.5k citations), Orthopedics and Sports Medicine (1.3k citations), Pulmonary and Respiratory Medicine (2.6k citations) and Radiology, Nuclear Medicine and Imaging (1.6k citations). Alison Stopeck has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Daniel F. Hayes, Michael Craig Miller, G. Thomas Budd, Jeri Matera, Leon W.M.M. Terstappen, Gerald V. Doyle, Massimo Cristofanilli, W. Jeffrey Allard, Matthew J. Ellis and James M. Reuben. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, European Journal of Cancer and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact